TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy

Journal of Clinical Investigation

Volumn 125, Issue 1, 2015, Pages 425-436

  Hu, Zheng ^a   Ding, Wencheng ^a   Zhu, Da ^a   Yu, Lan ^a   Jiang, Xiaohui ^a   Wang, Xiaoli ^a   Zhang, Changlin ^a   Wang, Liming ^a   Ji, Teng ^a   Liu, Dan ^a   He, Dan ^a   Xia, Xi ^b   Zhu, Tao ^a   Wei, Juncheng ^a   Wu, Peng ^a   Wang, Changyu ^a   Xi, Ling ^a   Gao, Qinglei ^a   Chen, Gang ^a   Liu, Rong ^a   Li, Kezhen ^a   Li, Shuang ^a   Wang, Shixuan ^a   Zhou, Jianfeng ^a   Ma, Ding ^a   Wang, Hui ^a   more..

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CYCLIN DEPENDENT KINASE 2; DNA; HISTONE H2AX; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSCRIPTION FACTOR E2F1; VIRUS DNA; ANTINEOPLASTIC AGENT; DEOXYRIBONUCLEASE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE ARREST; CONTROLLED STUDY; CROSS REACTION; DNA BINDING; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; DOWNSTREAM PROCESSING; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE DOSAGE; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC CODE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MOUSE; MUTAGENIC ACTIVITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHENOTYPE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS ONCOGENE; WART VIRUS; WART VIRUS RELATED CERVICAL CANCER; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; DNA CLEAVAGE; DRUG SCREENING; GENETICS; HEK293 CELL LINE; NUDE MOUSE; PAPILLOMAVIRUS INFECTIONS; TRANSGENIC MOUSE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; DEOXYRIBONUCLEASES; DNA CLEAVAGE; DNA, VIRAL; FEMALE; HEK293 CELLS; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920484581     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78206     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889-899.
3. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76-79.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-350.
5. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced car-cinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505-1511.
6. Spangle JM, Munger K. The HPV16 E6 oncopro-tein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog. 2013;9(3):e1003237.
7. Arroyo M, Bagchi S, Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol. 1993;13(10):6537-6546.
8. McIntyre MC, Ruesch MN, Laimins LA. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology. 1996;215(1):73-82.
9. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934-937.
10. Sima N, et al. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregula-tion of Rb and p53. Apoptosis. 2008;13(2):273-281.
11. Wang W, et al. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo. Cancer Lett. 2010;291(1):67-75.
12. Szczepek M, Brondani V, Buchel J, Serrano L, Segal DJ, Cathomen T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol. 2007;25(7):786-793.
13. Cermak T, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011;39(12):e82.
14. Miller JC, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011;29(2):143-148.
15. Doyon Y, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Me thods. 2011;8(1):74-79.
16. Guo J, Gaj T, Barbas CF 3rd. Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol. 2010;400(1):96-107.
17. Kim H, Um E, Cho SR, Jung C, Kim H, Kim JS. Surrogate reporters for enrichment of cells with nuclease-induced mutations. Nat Methods. 2011;8(11):941-943.
18. Perez-Pinera P, Ousterout DG, Brown MT, Gersbach CA. Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases. Nucleic Acids Res. 2012;40(8):3741-3752.
19. Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24(6):1012-1019.
20. Kim JM, Kim D, Kim S, Kim JS. Genotyping with CRISPR-Cas-derived RNA-guided endonu-cleases. Nat Commun. 2014;5:3157.
21. Arbeit JM, Munger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol. 1994;68(7):4358-4368.
22. Grau J, Boch J, Posch S. TALENoffer: genome-wide TALEN off-target prediction. Bioinformat-ics. 2013;29(22):2931-2932.
23. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-560.
24. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science. 2009;326(5959):1501.
25. Boch J, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326(5959):1509-1512.
26. Sudenga SL, Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int J Infect Dis. 2013;17(4):e216-e220.
27. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361(3):271-278.
28. Flanagan SM, Wilson S, Luesley D, Damery SL, Greenfield SM. Adverse outcomes after colpos-copy. BMC Womens Health. 2011;11:2.
29. Kaina B. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol. 2003;66(8):1547-1554.
30. Hodge LS, et al. Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecol Oncol. 2012;127(1):121-125.
31. Gupta S, Gabrani R, Ali J, Dang S. Exploring novel approaches to vaginal drug delivery. Recent Pat Drug Deliv Formul. 2011;5(2):82-94.
32. Srikrishna S, Cardozo L. The vagina as a route for drug delivery: a review. Int Urogynecol J. 2013;24(4):537-543.
33. Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
34. Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-826.
35. Fu Y, et al. High-frequency off-target mutagene-sis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.
36. Ran FA, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380-1389.
37. Denny L, et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA. 2005;294(17):2173-2181.
38. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9(suppl 1):S3-S8.
39. Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Bradlow HL. Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2957-2964.
40. Palliser D, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006;439(7072):89-94.
41. Stanley MA, Browne HM, Appleby M, Minson AC. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer. 1989;43(4):672-676.
42. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. 2012;30(5):460-465.
43. Garimberti E, Tosi S. Fluorescence in situ hybridization (FISH), basic principles and methodology. Methods Mol Biol. 2010;659:3-20.
44. Summersgill BM, Shipley JM. Fluorescence in situ hybridization analysis of formalin fixed paraffin embedded tissues, including tissue microarrays. Methods Mol Biol. 2010;659:51-70.
45. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.